Calidi Biotherapeutics Inc. to Showcase RedTail Platform and Oncology Advancements in Investor Webinar
July 22nd, 2025 2:26 PM
By: Newsworthy Staff
Calidi Biotherapeutics Inc. (NYSE American: CLDI) will host an investor webinar to discuss its RedTail platform and advancements in oncology, highlighting preclinical successes and future commercialization strategies.
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company, is set to host an investor webinar on July 24, 2025, focusing on its RedTail(TM) platform and recent oncology advancements. The webinar, led by CEO Eric Poma, Ph.D., will delve into the company's systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection. Highlighting preclinical data, the event will showcase the efficacy of lead candidate CLD-401, which demonstrated tumor elimination and immune memory activation. Calidi is advancing toward an Investigational New Drug (IND) filing and exploring strategic pharmaceutical partnerships to facilitate commercialization. Following the presentation, attendees will have the opportunity to engage in a Q&A session. For more details, visit https://ibn.fm/zIp8d.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
